Optimistic Buy Rating for CalciMedica Backed by Strong Financials and Promising Clinical Trials

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on CalciMedica (CALC – Research Report), retaining the price target of $20.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including CalciMedica’s recent financial performance and its promising clinical developments. In the first quarter of 2024, CalciMedica reported earnings that surpassed both internal and consensus estimates, primarily due to the valuation of financial instruments. This positive financial outcome, coupled with a strong cash position anticipated to support the company into the second half of 2025, lays a stable foundation for its ongoing operations.
Additionally, Pantginis perceives the company’s lead clinical candidate, Auxora, as a solid investment due to its involvement in multiple Phase 2 trials targeting a range of inflammatory diseases with significant unmet medical needs. The anticipated near-term release of topline data from the Phase 2b CARPO study in acute pancreatitis and the initiation of the Phase 2 KOURAGE trial for acute kidney injury, along with positive preclinical findings, strengthen the conviction in CalciMedica’s potential. These factors collectively underpin Pantginis’s optimistic Buy rating for CalciMedica’s stock.

According to TipRanks, Pantginis is a 5-star analyst with an average return of 12.7% and a 40.76% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Palatin Technologies, and Viking Therapeutics.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

CalciMedica (CALC) Company Description:

Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.